ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.712,68
0,34%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Viracta Therapeutics Inc (VIRX)

  7. Viracta Therapeutics Inc (VIRX) News

VIRX

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VIRX
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202422h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
30/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/05/202422h05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantsNASDAQ:VIRXViracta Therapeutics Inc
16/05/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
16/05/202422h23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/05/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
14/05/202413h00GlobeNewswire Inc.Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerNASDAQ:VIRXViracta Therapeutics Inc
09/05/202423h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRXViracta Therapeutics Inc
09/05/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
09/05/202422h05GlobeNewswire Inc.Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
07/05/202422h05GlobeNewswire Inc.Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VIRXViracta Therapeutics Inc
15/04/202414h00GlobeNewswire Inc.Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaNASDAQ:VIRXViracta Therapeutics Inc
01/04/202414h30GlobeNewswire Inc.Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanNASDAQ:VIRXViracta Therapeutics Inc
07/03/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRXViracta Therapeutics Inc
07/03/202422h19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRXViracta Therapeutics Inc
07/03/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
07/03/202422h05GlobeNewswire Inc.Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
29/02/202414h00GlobeNewswire Inc.Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialNASDAQ:VIRXViracta Therapeutics Inc
28/02/202402h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRXViracta Therapeutics Inc
28/02/202401h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
28/02/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/02/202403h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VIRXViracta Therapeutics Inc
06/02/202422h05GlobeNewswire Inc.Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:VIRXViracta Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.Viracta Therapeutics Provides Clinical Update and Outlook for 2024NASDAQ:VIRXViracta Therapeutics Inc
12/12/202314h00GlobeNewswire Inc.Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaNASDAQ:VIRXViracta Therapeutics Inc
04/12/202322h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
04/12/202314h30GlobeNewswire Inc.Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNASDAQ:VIRXViracta Therapeutics Inc
29/11/202301h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
29/11/202301h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/11/202323h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRX

Kürzlich von Ihnen besucht

BIT
I05054
Banca IMI
BIT
F19588
Vontobel Financial Produ...
BIT
UC1C4S
Unicredit Bank
BIT
P1CMW6
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten